BACKGROUND: Previous studies have suggested that DNA repair enzyme polymorphisms may bear prognostic value in metastatic colorectal carcinoma (MCRC). METHODS: We prospectively treated 43 MCRC patients with irinotecan-based regimens (XELIRI or IFL). Allelic variants of the XRCC1 gene at codon 399 and XPD gene at codon 751 were analyzed in lymphocyte DNA by PCR-RFLP. Clinical outcome variables: overall survival (OAS), progression-free survival (PFS) and the occurrence of grade 3 or 4 hematological and gastrointestinal (GIS) toxicities were evaluated. RESULTS: In the univariate analysis for OAS (n = 43) only XPD and XRCC1 polymorphisms were significant (P = 0.05 and P = 0.04, respectively). After adjustment for performance status (ECOG = 0, 1 vs. 2) and disease extent (single vs. multiple metastatic site), XRCC1 genotype and performance status retained significance (HR = 2.85, P = 0.04, and HR = 3.19, P = 0.02, respectively). Gln/Gln genotype was associated with the greatest risk of death. Type of presentation (metastatic vs. local disease at first presentation) was the only significant predictor of PFS in the univariate analysis (n = 40, P = 0.003). After adjustment for performance status and disease extent, type of presentation retained its significance (HR = 4.35, P = 0.003). None of the toxicities was associated with these genotypes. CONCLUSIONS: XRCC1 genotype independently predicted overall survival in metastatic colorectal carcinoma patients treated with irinotecan-based chemotherapy.
BACKGROUND: Previous studies have suggested that DNA repair enzyme polymorphisms may bear prognostic value in metastatic colorectal carcinoma (MCRC). METHODS: We prospectively treated 43 MCRC patients with irinotecan-based regimens (XELIRI or IFL). Allelic variants of the XRCC1 gene at codon 399 and XPD gene at codon 751 were analyzed in lymphocyte DNA by PCR-RFLP. Clinical outcome variables: overall survival (OAS), progression-free survival (PFS) and the occurrence of grade 3 or 4 hematological and gastrointestinal (GIS) toxicities were evaluated. RESULTS: In the univariate analysis for OAS (n = 43) only XPD and XRCC1 polymorphisms were significant (P = 0.05 and P = 0.04, respectively). After adjustment for performance status (ECOG = 0, 1 vs. 2) and disease extent (single vs. multiple metastatic site), XRCC1 genotype and performance status retained significance (HR = 2.85, P = 0.04, and HR = 3.19, P = 0.02, respectively). Gln/Gln genotype was associated with the greatest risk of death. Type of presentation (metastatic vs. local disease at first presentation) was the only significant predictor of PFS in the univariate analysis (n = 40, P = 0.003). After adjustment for performance status and disease extent, type of presentation retained its significance (HR = 4.35, P = 0.003). None of the toxicities was associated with these genotypes. CONCLUSIONS:XRCC1 genotype independently predicted overall survival in metastatic colorectal carcinomapatients treated with irinotecan-based chemotherapy.
Authors: D W Rea; J W R Nortier; W W Ten Bokkel Huinink; S Falk; D J Richel; T Maughan; G Groenewegen; J M Smit; N Steven; J M Bakker; D Semiond; D J Kerr; C J A Punt Journal: Ann Oncol Date: 2005-06-06 Impact factor: 32.976
Authors: S K Quinney; S P Sanghani; W I Davis; T D Hurley; Z Sun; D J Murry; W F Bosron Journal: J Pharmacol Exp Ther Date: 2005-02-01 Impact factor: 4.030
Authors: Janelle M Hoskins; Eugenio Marcuello; Albert Altes; Sharon Marsh; Taylor Maxwell; Derek J Van Booven; Laia Paré; Robert Culverhouse; Howard L McLeod; Montserrat Baiget Journal: Clin Cancer Res Date: 2008-03-15 Impact factor: 12.531
Authors: Julie K Horton; Mary Watson; Donna F Stefanick; Daniel T Shaughnessy; Jack A Taylor; Samuel H Wilson Journal: Cell Res Date: 2008-01 Impact factor: 25.617
Authors: Michael S Braun; Susan D Richman; Philip Quirke; Catherine Daly; Julian W Adlard; Faye Elliott; Jennifer H Barrett; Peter Selby; Angela M Meade; Richard J Stephens; Mahesh K B Parmar; Matthew T Seymour Journal: J Clin Oncol Date: 2008-06-01 Impact factor: 44.544
Authors: Rikke Dalgaard Hansen; Mette Sørensen; Anne Tjønneland; Kim Overvad; Håkan Wallin; Ole Raaschou-Nielsen; Ulla Vogel Journal: Mutat Res Date: 2007-02-12 Impact factor: 2.433
Authors: Mustafa Unal; Mehmet Güven; Bahadir Batar; Ahmet Ozaydin; Ahmet Sarici; Kazim Devranoğlu Journal: Exp Eye Res Date: 2007-06-14 Impact factor: 3.467
Authors: A Ruzzo; F Graziano; F Loupakis; D Santini; V Catalano; R Bisonni; R Ficarelli; A Fontana; F Andreoni; A Falcone; E Canestrari; G Tonini; D Mari; P Lippe; F Pizzagalli; G Schiavon; P Alessandroni; L Giustini; P Maltese; E Testa; E T Menichetti; M Magnani Journal: Pharmacogenomics J Date: 2007-06-05 Impact factor: 3.550
Authors: Andrés López-Cortés; César Paz-Y-Miño; Santiago Guerrero; Gabriela Jaramillo-Koupermann; Ángela León Cáceres; Dámaris P Intriago-Baldeón; Jennyfer M García-Cárdenas; Patricia Guevara-Ramírez; Isaac Armendáriz-Castillo; Paola E Leone; Luis Abel Quiñones; Juan Pablo Cayún; Néstor W Soria Journal: Pharmacogenomics J Date: 2019-10-15 Impact factor: 3.550